Ciluprevir

Known as: (2R,6S,12Z,13aS,14aR,16aS)-6-(((Cyclopentyloxy)carbonyl)amino)-2-((7-methoxy-2-(2-((1-methylethyl)amino)thiazol-4-yl)quinolin-4-yl)oxy)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecine-14a(5H)-carboxylic acid 
An orally bioavailable, peptidomimetic, macrocyclic compound with activity against hepatitis C virus (HCV). Ciluprevir binds non-covalently to the… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2016
0120052016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
OBJECTIVE Direct-acting antivirals (DAAs) inhibit hepatitis C virus (HCV) infection by targeting viral proteins that play… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2015
2015
The treatment of patients with chronic HCV infection has been revolutionized by the approval of a number of direct acting anti… (More)
Is this relevant?
2014
2014
To aid the design of next generation hepatitis C virus (HCV) drugs, the kinetics of the interactions between NS3 protease… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?
2008
2008
The first potent and specific inhibitor of the NS3/4A serine protease to be tested in a randomized, placebocontrolled pilot study… (More)
Is this relevant?
Review
2007
Review
2007
This perspective is the fifth in a series discussing drugs dropped from development in 2005, of which 11 were being developed for… (More)
Is this relevant?
Review
2006
Review
2006
Hepatitis C virus (HCV) NS3.4A protease inhibitors have potential for treating chronic HCV disease. Robust antiviral effects have… (More)
Is this relevant?
Review
2005
Review
2005
Hepatitis C virus (HCV) infection is a serious cause of chronic liver disease worldwide and afflicts > 170 million people. The… (More)
Is this relevant?